SMS Pharmaceuticals Q2 FY27: revenue up 30.4% to ₹316 Cr, net profit up 57.7% to ₹40 Cr
Results · Finvezto · 4 Nov 2026 · SMS Pharmaceuticals (SMSPHARMA)
Results Q2 FY27, ₹ Cr
| Q2 FY27 | ₹ Cr | QoQ | YoY |
|---|---|---|---|
| Revenue | 316 | +52.7% | +30.4% |
| Operating profit | 68 | +65.1% | +39.9% |
| Net profit | 40 | +90.9% | +57.7% |
| Operating margin | 21.4% | +1.6 pp | +1.5 pp |
| Net margin | 12.6% | +2.5 pp | +2.2 pp |
Key points
- SMS Pharmaceuticals reported revenue from operations of Rs 316.08 crore for Q2 FY27, up 30% from Rs 242.43 crore in Q2 FY26, with EBITDA rising 40% to Rs 67.65 crore and net profit up 57% to Rs 39.57 crore. NSE filing
- Growth was driven by strong volume gains and improved price realizations in anti-inflammatory and antiretroviral APIs, supported by gross margin expansion from backward integration. NSE filing
- Revenue was ₹316 Cr, up 30.4% on a year earlier and up 52.7% on the quarter before. Finvezto data
Other figures
- Gross profit (Incl. manufacturing expenses): ₹111 Cr (+41.0% YoY)
What to watch
- Operating margin over the last 4 quarters (Dec 25, Mar 26, Jun 26, Sep 26): 20.7%, 16.8%, 19.8%, 21.4%.
- Net profit over the last 4 quarters (Dec 25, Mar 26, Jun 26, Sep 26), ₹ Cr: 24, 33, 21, 40.
Links
NSE filing (PDF) · Company page · Results tracker
Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630.